People
Shares of Arcturus Therapeutics are up nearly 10 percent this morning after the company announced it reached a settlement with its former chief executive officer and replaced four members of its board of directors with four new ones.
After Axovant Sciences’ spectacular clinical trial failure in September 2017, the company has been reorganizing. Today it announced it had completed that reorganization by adding to its executive team and Scientific Advisory Board.
The general consensus is that only about seven to nine percent of chief executive roles in biotech are filled by women. As low as that sounds, it’s better than in the Fortune 500, where only about 4.2 percent are led by female chief executives.
There have been a number of leadership changes in the life sciences industries over the past week. BioSpace compiled a roundup of the changing landscape of the c-suite and boards of directors across the industry.
A tangled web has been woven at Michigan-based Rockwell Medical. The board of directors has fired the chief executive officer and chief financial officer.
Despite the advances in personalized medicine, a new survey of 1,001 Americans shows that the majority are not familiar with the concept.
Two months after walking away from his role as head of R&D and chief scientific officer at Gilead Sciences, Norbert Bischofberger has re-emerged at the helm of startup Kronos Bio, Inc.
The mysterious death of a biotech startup chief executive officer in late April projected the term biohacker into the forefront of the industry lexicon.
Celgne’s head of business development, George Golumbeski, has also left the company.
AstraZeneca has a problem. Not with its pipeline, but with the way a significant chunk of shareholders views its executive pay program.
PRESS RELEASES